Back to News
Market Impact: 0.15
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Helus Pharma, formerly Cybin (NASDAQ: HELP), presented late-stage development plans for HLP-003 as an adjunctive treatment for major depressive disorder at TD Cowen's neuropsychiatry summit. The company also discussed its broader pipeline of serotonergic agonists, but disclosed no clinical data, regulatory milestones, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
HELP0.20
More News
- Jensen Huang’s $21 billion net worth in AI rout—Nvidia’s recovery will be ‘capped’ after he admitted affair with alleged Chinese spy
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Weekend trading of Nvidia scandal shines light on new financial products